The new service, which Scalable said was a first ⁠for ⁠a European bank, comes in addition to the app and website as ways to access customer...

For years, owning power meant betting on a slow, steady rise in demand as the economy grew. That story has suddenly changed. The machines b...

In today’s world, investors cannot assume that correlations that worked in the past will work in exactly the same manner now. We are in a p...

Indian private credit funds are adopting artificial intelligence for deal sourcing and analysis. Most funds use AI moderately for data anal...

Given current market conditions, better stick with stocks that offer some comfort. It could be valuation, or growth purely dependent on dom...

Global fund managers hold the highest equity proportion since late 2021. Rising bond yields are seen as a significant threat to stock marke...

Consider how things have panned out for the banking sector in Q1 FY27. The quality of loan books has improved. Though credit growth was not...

There are currently too many variables that can move the markets in either direction. Oil prices may have settled into a range for now, but...

The AI investment debate is shifting toward identifying sustainable winners as spending accelerates. Hyperscalers, semiconductor firms and ...

Nestle is developing specialized products for GLP-1 weight-loss drug users. Artificial intelligence aids in analyzing research and identify...

Indian equities may stay supported by a resilient domestic economy, but future returns are likely to depend more on earnings growth than va...

In July, mutual funds increased their allocation to the IT sector to 6.6 per cent, marking a positive shift after an extended period of min...

AI is a tool to enhance human investment judgment, not replace it. Investors increasingly use AI to test existing ideas rather than generat...

State Bank of India underwrote nearly one lakh crore rupees in MSME loans using artificial intelligence. AI is also automating the processi...

Sometimes the real market story is not in the headline index. The Nifty and Sensex can be under pressure, and yet, below them, mid- and sma...

For Indian pharma, the regulatory risk is still real. A US FDA inspection can still cause trouble. A plant making an important product or g...

The commitments show that a substantial part of Big Tech's AI spending spree has already been locked in, without yet appearing as debt-like...